Open Label Study to Assess the Safety of REL-1017 for Major Depressive Disorder
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a 1-year open-label study to access the safety of REL-1017 once daily (QD) as an
adjunctive treatment of Major Depressive Disorder. Study participants will continue to take
their current antidepressant therapy in addition to the study drug for the duration of the
treatment period.